Background. One of the most active chemotherapy combinations in advanced or recurrent cervical cancer is cis-platin-paclitaxel. However, this palliative regimen is associated with significant toxicity. Carboplatin-paclitaxel is thus an attractive option. Methods. Patients with advanced or recurrent carcinoma of the cervix treated with carboplatin-paclitaxel from April 2000 were included in the study. Starting doses of carboplatin-paclitaxel were: AUC 5-6 and 155-175 mg/m2, respectively, repeated every 28 days. Results. Twenty-five women treated with this combination were identified. Twenty-three women (92% ) had prior treatment with pelvic radiotherapy and 14 (56% ) had had concurrent radio-sensitizing cisplatin. There was a 20% PR and a 20% CR rate (10/25). The median progression-free survival for the entire group was 3 months. Responders had a median PFS of 16 months. Fourteen patients (56% ) had died of disease progression. The median overall survival (OS) was 21 months. Common toxicities included: grade 1 or 2 anemia, 68% ; grade 3 or 4 anemia, 32% ; grade 3 or 4 neutropenia, 32% ; and grade 1 or 2 peripheral neuropathy, 24% . ECOG PS did not change significantly while on treatment. Eighty-four percent of treatments were delivered on time, and 96% at full dose. Conclusions. Carboplatinpaclitaxel is an active combination in advanced and recurrent cervical cancer. In this predominantly pre-irradiated group, the combination was deliverable, well tolerated, and the most commonly observed toxicity was anemia.1078. A phase Ⅱ evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: A Gynecologic Oncology Group study Grendys Jr. E.C./Blessing J.A./Burger R./Hoffman J. E.C. Grendys Jr., Florida Gynecologic Oncology, 2780 Cleveland Avenue, Fort Myers, FL 33901, United States -GYNECOL. ONCOL. 2005, 98/2 (249-253) Objective. A phase Ⅱ study was conducted to determine the efficacy of single agent flavopiridol therapy in patients with recurrent or persistent endometrial adenocarcinoma refractory to established treatments. Methods. Eligible patients with measurable disease who failed primary therapy including one cytotoxic regimen were eligible for the trial. They were treated with single agent flavopiridol (50 mg/m2/day, Ⅳ bolus days 1, 2, 3). Treatment was repeated every 21 days with dose adjustments made for toxicity. Patients were treated until progression of disease or adverse side effects precluded further therapy. Results. A total of 26 patients were enrolled in the study of whom, 23 patients were eligible. There were no objective responses. Five patients had stable disease (22% ), 15 (65% ) had increasing disease, and response could not be assessed in 3 (13% ). The most frequent side effects included anemia, neutropenia, and diarrhea, all of which appeared manageable. Conclusion. Flavopiridol as a single agent in the above dosing schedule appears to have minimal activity as second-line chemotherapy of endometrial adenocarcinoma.
展开▼
